View Single Post
Old 03-19-2019, 12:11 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is online now
Dave @ ActiveMSers
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,859

BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS


Enrollment Announced During MS Awareness Week

NEW YORK and CLEVELAND, March 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the first patient has been enrolled in its Phase 2 open-label, multicenter study of repeated intrathecal administration of autologous MSC-NTF cells in participants with progressive Multiple Sclerosis (MS).

Chaim Lebovits, president and CEO of BrainStorm stated, “Midway through MS Awareness Week: March 10-16, we are pleased to announce the first participant with progressive MS has been enrolled in our Phase 2 clinical trial. Progressive MS has deeply affected the lives of many and dramatically impacted family members, caregivers and others. Today, there is no U.S. FDA approved therapy addressing more than one progressive form of MS and we are pleased to deploy our NurOwn® technology platform in this new indication. Soon, we will announce additional sites where the clinical trials will be conducted.”

“The first participant enrolled in our Phase 2 trial represents an important milestone in our commitment to address the unmet medical need in progressive MS,” said Ralph Kern, MD MHSc, Chief Operating and Chief Medical Officer of Brainstorm. “We plan to quickly initiate enrollment across all study sites and look toward top line data by the middle of 2020.”

MS is a chronic neuroinflammatory and neurodegenerative disorder that affects the brain and spinal cord. MS affects approximately 1 million individuals in the U.S. and 2.5 million individuals worldwide. Approximately half of affected individuals will eventually develop a progressive form of the disease, which may lead to increased levels of motor, visual, and cognitive functional impairment and disability.

For more information, refer to, using the NCT identifier (NCT03799718).
Dave Bexfield
Reply With Quote